Supplementary Online Content Basaria S, Harman SM, Travison TG, et al. The effects of testosterone administration for three years on subclinical atherosclerosis progression in older men with low or low normal testosterone levels: a randomized clinical trial. JAMA. doi:10.1/jama.2015.8881 etable 1. Comparison of baseline characteristics by trial completion status, mean (standard deviation) or N (%) shown etable 2. Adverse events associated with randomization to testosterone or placebo arms efigure 1. Participant level three year change in carotid artery intima media thickness (CCA IMT) and coronary artery calcification (CAC), by randomization group, among participants in the completer sample efigure 2. Association between change in circulating total testosterone (TT) & calculated free testosterone (cft) levels and change in common carotid artery intima media thickness (CCA IMT) & coronary artery calcification (CAC), using data observed on participants assigned to testosterone replacement efigure 3. Baseline and on treament data obtained using the Cancer Rehabilitation Evaluation System Short Form (CARES SF) Marital Subscale efigure 4. Baseline and on treament data obtained using the physical functioning scale of the MOS 36 item short form health survey (SF 36) efigure 5. Baseline and on treatment health related quality of life data acquired using the MOS 36 item short form health survey (SF 36), summarized by domain and overall score efigure 6. Exploratory subgroup analyses of testosterone effects by participant subcategories of men who had coronary artery disease (CAD) or diabetes, or who were obese or statin users at baseline This supplementary material has been provided by the authors to give readers additional information about their work. 2015 American Medical Association. All rights reserved.
! Supplementary Table 1. Comparison of baseline characteristics by trial completion status, mean (standard deviation) or N (%) shown. Completed Trial (N = 211) Did not complete trial (N = 95) Age, years 67.2 (5.0) 68.3 (5.4) BMI, kg/m 2 28.1 (2.8) 28.0 (3.0), ng/dl 306 (66) 310 (64) CCA-IMT, mm 0.88 (0.19) 0.88 (0.23) CAC, AU 443 (681) 565 (754)!!!
Supplementary Table 2. Adverse events associated with randomization to testosterone or placebo arms (N = 155) (N = 151) Participants Participants Number of Number of reporting one or reporting one Events Events more events or more events Cardiovascular 28 20 24 16 0.65 Dermatologic 15 14 13 12 0.76 Endocrine/Metabolic 8 7 6 6 0.63 Gastrointestinal 14 11 17 12 0.54 Genital/Urinary 41 32 31 27 0.29 Hematologic 17 15 4 4 0.011 Hepatic/Biliary 1 1 1 1 0.99 Infectious Disease - - 3 3 >0.99 Lymphatic - - 2 2 >0.99 Musculoskeletal 37 30 36 27 >0.99 Neurologic 4 4 5 4 0.71 Other 18 16 21 18 0.57 Psychiatric 4 4 5 5 0.71 Pulmonary 21 20 33 27 0.09 SAE 33 25 33 24 0.92 a p a Wald test derived from Poisson regression of count of events per subject on treatment intervention. Thirteen participants in the testosterone arm experienced a hematocrit >54% compared to no participant in the placebo arm. More men in the testosterone (n=14) than placebo (n=2) arm had an IPSS score >21. Major Adverse Cardiovascular Events (MACE) in the testosterone and placebo groups, respectively, were as follows: myocardial infarction: 3 vs 2; coronary revascularization procedure: 5 vs 2; stroke: 3 vs 0; cardiovascular-related death: 1 vs 0.!
Supplementary Figure 1 CCA IMT, mm CAC, AU 0.50 2000 0.25 0 0.00 0 0.25 0 0.50 2000 (N = 92) (N = 101) (N = 92) (N= 92) Participant level three year change in carotid artery intima media thickness (CCA IMT) and coronary artery calcification (CAC), by randomization group, among participants in the completer sample. Boxplots show medians (dark horizontal lines), 25th and 75th percentiles (top and bottom, respectively, of solid boxes), upper and lower hinges (dashed lines, extending from 25th and 75th percentiles to the outermost data points within 1.5 interquartile intervals of those percentiles), and values lying outside these ranges (single data points).
Supplementary Figure 2 Change in CCA IMT, mm 0.2 0.1 0.0 0.1 N = 126 0.2 0.1 0.0 0.1 N = 120 300 0 300 0 0 1200 0 200 300 400 Change in CAC, AU 0 400 0 400 N = 102 0 400 0 400 N = 97 300 0 300 0 0 1200 0 200 300 400 Change in TT, ng/dl Change in cft, pg/ml Association between change in circulating total testosterone (TT) & calculated free testosterone (cft) levels and change in common carotid artery intima media thickness (CCA IMT) & coronary artery calcification (CAC), using data observed on participants assigned to testosterone replacement. Participants' changes in CCA IMT and CAC are summarized as linear trends with time, scaled to one year. Change in total and free testosterone is taken as the difference between mean on treatment and baseline values. Fitted smooths (blue lines) are obtained via a generalized additive model. Deviance explained for each of these models was less than 0.5%, indicated marked lack of evidence of association.
Supplementary Figure 3 Marital Interaction and Intimacy 6 Difference: 0.14 ( 0.45, 0.74); p = 0.64 5 4 3 2 86 77 72 75 85 Baseline and on treament data obtained using the Cancer Rehabilitation Evaluation System Short Form (CARES SF) Marital Subscale. Sample means and 95% confidence intervals shown for each visit and arm are based on observed data. The model based estimate of on treatment difference between arms, controlling for age group and study center, and accommodating missing records via multiple imputation, is provided in italicized text. The number of observed data points at each visit is provided along the horizontal axis.
Supplementary Figure 4 Self Reported Physical Functioning Difference: 0.5 ( 3.6, 2.7); p = 0.78 95 85 131 116 112 95 136 120 108 Baseline and on treament data obtained using the physical functioning scale of the MOS 36 item short form health survey (SF 36). Sample means and 95% confidence intervals shown for each visit and arm are based on observed data. The model based estimate of on treatment difference between arms, controlling for age group and study center, and accommodating missing records via multiple imputation, is provided in italicized text. The number of observed data points at each visit is provided along the horizontal axis.
Supplementary Figure 5 Energy / Fatigue Emotional Well Being Role Limitations, Emotional Problems Difference: 2.0 ( 6.3, 2.3); p = 0.37 Difference: 2.8 ( 6.2, 0.7); p = 0.11 Difference: 1.3 ( 5.7, 8.2); p = 0.72 51 41 39 51 41 39 51 41 39 Social Functioning Physical Functioning Role Limitations, Physical Health Difference: 1.5 ( 6.2, 3.2); p = 0.54 Difference: 0.6 ( 6.4, 5.3); p = 0.85 Difference: 2.1 ( 6.2, 10.4); p = 0.61 51 41 39 51 41 39 51 41 39 Pain General Health Overall Score Difference: 0.6 ( 5.9, 4.7); p = 0.84 Difference: 0.04 ( 4.7, 4.7); p = 0.99 Difference: 0.4 ( 4.3, 3.6); p = 0.86 51 41 39 51 41 39 51 41 39 Baseline and on treatment health related quality of life data acquired using the MOS 36 item short form health survey (SF 36), summarized by domain and overall score. Data on the full SF 36 were obtained at the Charles R. Drew University and Boston University centers. Sample means and 95% confidence intervals shown for each visit and arm are based on observed data. Model based estimates of on treatment difference between arms, controlling for age group and study center, and accommodating missing records via multiple imputation, are provided on each panel in italicized text. Number of observed data points at each visit is provided along the horizontal axis.
Supplementary Figure 6 CCA IMT, mm N Slope Difference (95% CI) N Slope Difference (95% CI) CAD No CAD 22 128 0.0169 (0.0115, 0.0223) 0.0095 (0.007, 0.0121) 24 131 0.0129 (0.008, 0.0178) 0.0121 (0.0102, 0.014) Diabetic Nondiabetic 24 126 0.0163 (0.0107, 0.0218) 0.0092 (0.0066, 0.0118) 22 133 0.0115 (0.0049, 0.0182) 0.0123 (0.0105, 0.0141) Obese Nonobese 42 108 0.01 (0.0068, 0.0132) 0.0107 (0.0077, 0.0136) 40 115 0.0096 (0.0056, 0.0135) 0.0132 (0.0112, 0.0151) Statin Use No Statin Use Results more supportive of testosterone 65 86 0.0091 (0.005, 0.0131) 0.0118 (0.0094, 0.0142) Results more supportive of placebo 68 87 0.0111 (0.0088, 0.0134) 0.0131 (0.0105, 0.0157) 0.02 0.00 0.02 0.04 Per Year Difference, v., mm CAC, AU N Slope Difference (95% CI) N Slope Difference (95% CI) CAD No CAD 22 128 42 ( 50, 134) 41 (28, 54) 24 131 79 ( 3, 161) 26 (13, 38) Diabetic Nondiabetic 24 126 37 ( 1, 74) 43 (23, 62) 22 133 72 ( 28, 171) 28 (16, 40) Obese Nonobese 42 108 48 (7, 88) 39 (21, 57) 40 115 48 (4, 93) 29 (14, 44) Statin Use No Statin Use Results more supportive of testosterone 65 86 35 (12, 58) 47 (21, 72) Results more supportive of placebo 68 87 56 (25, 87) 19 (2, 35) 200 0 200 Per Year Difference, v., AU Exploratory subgroup analyses of testosterone effects by participant subcategories of men who had coronary artery disease (CAD) or diabetes, or who were obese or statin users at baseline. The per year intervention effect (the estimated difference between the testosterone and placebo groups in per year change in CCA IMT and CAC) in each subgroup is shown along with the accompanying 95% confidence interval. The point estimates to the left of zero indicate that randomization to the testosterone arm was associated with lower rates of subclinical atherosclerosis progression than randomization to the placebo arm, and the point estimates to the right of zero indicate that randomization to testosterone was associated with greater rates of atherosclerosis progression than randomization to placebo. In the right margins, annotations provide point and 95% confidence interval estimates of per year change derived from analyses restricted to placebo and testosterone arms. All estimates were derived from mixed effects regression models controlling for age group and study center, and estimated using observed data (see Methods).